Cardiovascular effects of neurotension and some analogues on rats

Eugenio D. Di Paola, Elliott Richelson

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

When administered in vivo into the femoral vein of normotensive rats, neurotensin, neurotensin-(8-13), and [D-Lys8]neurotensin-(8-13) decreased diastolic blood pressure in a dose-dependent manner, without change in heart rate. All three peptides evoked tachyphylaxis and a triphasic depressor-pressor-depressor, response at higher doses. The rank order of potency was neurotensin > [D-Lys8]neurotensin-(8-13). In organ chamber experiments, both neurotensin and neurotensin-(8-13) at a range of concentrations which induced dose-dependent decreases in blood pressure, did not significantly change tension in rat aorta rings with or without endothelium. In contrast, [D-Lys8]neurotensin-(8-13) induced weak dose-dependent relaxation of both rings with or without endothelium. However, this effect was not obtained at concentrations able to decrease the blood pressure. Indomethacin did not change the vasodilator effect of [D-Lys8]neurotensin-(8-13). There was no correlation between the vasodilator effect of this peptide and its ability to decrease blood pressure. These experiments suggest that the hypotension was not due to a direct vasodilator effect on the smooth muscle. In addition, since the rank order of peptide potency was opposite of those found in previous studies of second messenger synthesis and binding to neural tissue, these data suggest that there is a second receptor for neurotensin or that neurotensin can also bind to a different unknown receptor.

Original languageEnglish (US)
Pages (from-to)279-283
Number of pages5
JournalEuropean Journal of Pharmacology
Volume175
Issue number3
DOIs
StatePublished - Jan 17 1990

Fingerprint

neurotensin (8-13)
Neurotensin
Blood Pressure
Vasodilator Agents
Peptides
Endothelium
Neurotensin Receptors
Tachyphylaxis
Femoral Vein
Second Messenger Systems
Indomethacin
Hypotension
Smooth Muscle
Aorta
Heart Rate

Keywords

  • Aorta (rat)
  • Blood pressure
  • Heart rate
  • Neurotensin
  • Neurotensin analogues

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Cardiovascular effects of neurotension and some analogues on rats. / Di Paola, Eugenio D.; Richelson, Elliott.

In: European Journal of Pharmacology, Vol. 175, No. 3, 17.01.1990, p. 279-283.

Research output: Contribution to journalArticle

Di Paola, Eugenio D. ; Richelson, Elliott. / Cardiovascular effects of neurotension and some analogues on rats. In: European Journal of Pharmacology. 1990 ; Vol. 175, No. 3. pp. 279-283.
@article{9c85469051ef4fff87f6a146cb81564c,
title = "Cardiovascular effects of neurotension and some analogues on rats",
abstract = "When administered in vivo into the femoral vein of normotensive rats, neurotensin, neurotensin-(8-13), and [D-Lys8]neurotensin-(8-13) decreased diastolic blood pressure in a dose-dependent manner, without change in heart rate. All three peptides evoked tachyphylaxis and a triphasic depressor-pressor-depressor, response at higher doses. The rank order of potency was neurotensin > [D-Lys8]neurotensin-(8-13). In organ chamber experiments, both neurotensin and neurotensin-(8-13) at a range of concentrations which induced dose-dependent decreases in blood pressure, did not significantly change tension in rat aorta rings with or without endothelium. In contrast, [D-Lys8]neurotensin-(8-13) induced weak dose-dependent relaxation of both rings with or without endothelium. However, this effect was not obtained at concentrations able to decrease the blood pressure. Indomethacin did not change the vasodilator effect of [D-Lys8]neurotensin-(8-13). There was no correlation between the vasodilator effect of this peptide and its ability to decrease blood pressure. These experiments suggest that the hypotension was not due to a direct vasodilator effect on the smooth muscle. In addition, since the rank order of peptide potency was opposite of those found in previous studies of second messenger synthesis and binding to neural tissue, these data suggest that there is a second receptor for neurotensin or that neurotensin can also bind to a different unknown receptor.",
keywords = "Aorta (rat), Blood pressure, Heart rate, Neurotensin, Neurotensin analogues",
author = "{Di Paola}, {Eugenio D.} and Elliott Richelson",
year = "1990",
month = "1",
day = "17",
doi = "10.1016/0014-2999(90)90565-N",
language = "English (US)",
volume = "175",
pages = "279--283",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Cardiovascular effects of neurotension and some analogues on rats

AU - Di Paola, Eugenio D.

AU - Richelson, Elliott

PY - 1990/1/17

Y1 - 1990/1/17

N2 - When administered in vivo into the femoral vein of normotensive rats, neurotensin, neurotensin-(8-13), and [D-Lys8]neurotensin-(8-13) decreased diastolic blood pressure in a dose-dependent manner, without change in heart rate. All three peptides evoked tachyphylaxis and a triphasic depressor-pressor-depressor, response at higher doses. The rank order of potency was neurotensin > [D-Lys8]neurotensin-(8-13). In organ chamber experiments, both neurotensin and neurotensin-(8-13) at a range of concentrations which induced dose-dependent decreases in blood pressure, did not significantly change tension in rat aorta rings with or without endothelium. In contrast, [D-Lys8]neurotensin-(8-13) induced weak dose-dependent relaxation of both rings with or without endothelium. However, this effect was not obtained at concentrations able to decrease the blood pressure. Indomethacin did not change the vasodilator effect of [D-Lys8]neurotensin-(8-13). There was no correlation between the vasodilator effect of this peptide and its ability to decrease blood pressure. These experiments suggest that the hypotension was not due to a direct vasodilator effect on the smooth muscle. In addition, since the rank order of peptide potency was opposite of those found in previous studies of second messenger synthesis and binding to neural tissue, these data suggest that there is a second receptor for neurotensin or that neurotensin can also bind to a different unknown receptor.

AB - When administered in vivo into the femoral vein of normotensive rats, neurotensin, neurotensin-(8-13), and [D-Lys8]neurotensin-(8-13) decreased diastolic blood pressure in a dose-dependent manner, without change in heart rate. All three peptides evoked tachyphylaxis and a triphasic depressor-pressor-depressor, response at higher doses. The rank order of potency was neurotensin > [D-Lys8]neurotensin-(8-13). In organ chamber experiments, both neurotensin and neurotensin-(8-13) at a range of concentrations which induced dose-dependent decreases in blood pressure, did not significantly change tension in rat aorta rings with or without endothelium. In contrast, [D-Lys8]neurotensin-(8-13) induced weak dose-dependent relaxation of both rings with or without endothelium. However, this effect was not obtained at concentrations able to decrease the blood pressure. Indomethacin did not change the vasodilator effect of [D-Lys8]neurotensin-(8-13). There was no correlation between the vasodilator effect of this peptide and its ability to decrease blood pressure. These experiments suggest that the hypotension was not due to a direct vasodilator effect on the smooth muscle. In addition, since the rank order of peptide potency was opposite of those found in previous studies of second messenger synthesis and binding to neural tissue, these data suggest that there is a second receptor for neurotensin or that neurotensin can also bind to a different unknown receptor.

KW - Aorta (rat)

KW - Blood pressure

KW - Heart rate

KW - Neurotensin

KW - Neurotensin analogues

UR - http://www.scopus.com/inward/record.url?scp=0025164845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025164845&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(90)90565-N

DO - 10.1016/0014-2999(90)90565-N

M3 - Article

C2 - 2323349

AN - SCOPUS:0025164845

VL - 175

SP - 279

EP - 283

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 3

ER -